与现代抗癌疗法相关的眼部表面毒性。

IF 5.1 2区 医学 Q1 OPHTHALMOLOGY
Rafael Boucher MD , Oscar Haigh PhD , Emmanuel Barreau MD , Stéphane Champiat MD, PhD , Olivier Lambotte MD, PhD , Clovis Adam MD , Marc Labetoulle MD, PhD , Antoine Rousseau MD, PhD
{"title":"与现代抗癌疗法相关的眼部表面毒性。","authors":"Rafael Boucher MD ,&nbsp;Oscar Haigh PhD ,&nbsp;Emmanuel Barreau MD ,&nbsp;Stéphane Champiat MD, PhD ,&nbsp;Olivier Lambotte MD, PhD ,&nbsp;Clovis Adam MD ,&nbsp;Marc Labetoulle MD, PhD ,&nbsp;Antoine Rousseau MD, PhD","doi":"10.1016/j.survophthal.2023.10.002","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span><span>Cancer treatments have recently shifted from broad-spectrum </span>cytotoxic therapies to more focused treatments, maximizing anticancerous activity while reducing toxicity to healthy cells. These modern </span>anticancer therapies (MATs) encompass a wide range of innovative molecules that include </span>immune checkpoint inhibitors<span><span> and other targeted anticancer therapies, comprising antibody drug conjugates<span> and inhibitors of signal transduction. Some MATs are associated with </span></span>ocular surface<span> adverse events that can cause severe discomfort and even lead to loss of vision. While these complications remain rare, they are probably underreported. It is likely that both oncologists and ophthalmologists will come across MATs-associated ocular surface-adverse events in their practices, owing to the increasing number of patients being treated with MATs. Rapid identification of ocular surface-adverse events is crucial, as early intervention can manage these conditions to avoid vision loss and reduce negative impacts on </span></span></span>quality of life. We discuss characteristics of ocular surface pathologies attributed to MATs, describe the suspected underlying pathophysiological mechanisms, and outline the main lines of treatment.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ocular surface toxicities associated with modern anticancer therapies\",\"authors\":\"Rafael Boucher MD ,&nbsp;Oscar Haigh PhD ,&nbsp;Emmanuel Barreau MD ,&nbsp;Stéphane Champiat MD, PhD ,&nbsp;Olivier Lambotte MD, PhD ,&nbsp;Clovis Adam MD ,&nbsp;Marc Labetoulle MD, PhD ,&nbsp;Antoine Rousseau MD, PhD\",\"doi\":\"10.1016/j.survophthal.2023.10.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span><span>Cancer treatments have recently shifted from broad-spectrum </span>cytotoxic therapies to more focused treatments, maximizing anticancerous activity while reducing toxicity to healthy cells. These modern </span>anticancer therapies (MATs) encompass a wide range of innovative molecules that include </span>immune checkpoint inhibitors<span><span> and other targeted anticancer therapies, comprising antibody drug conjugates<span> and inhibitors of signal transduction. Some MATs are associated with </span></span>ocular surface<span> adverse events that can cause severe discomfort and even lead to loss of vision. While these complications remain rare, they are probably underreported. It is likely that both oncologists and ophthalmologists will come across MATs-associated ocular surface-adverse events in their practices, owing to the increasing number of patients being treated with MATs. Rapid identification of ocular surface-adverse events is crucial, as early intervention can manage these conditions to avoid vision loss and reduce negative impacts on </span></span></span>quality of life. We discuss characteristics of ocular surface pathologies attributed to MATs, describe the suspected underlying pathophysiological mechanisms, and outline the main lines of treatment.</p></div>\",\"PeriodicalId\":22102,\"journal\":{\"name\":\"Survey of ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Survey of ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0039625723001340\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Survey of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039625723001340","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

癌症治疗最近已从广谱细胞毒性疗法转向更集中的治疗,最大限度地提高抗癌活性,同时降低对健康细胞的毒性。这些现代抗癌疗法(MATs)涵盖了广泛的创新分子,主要包括免疫检查点抑制剂(ICIs)和靶向抗癌疗法(TATs),包括抗体-药物偶联物(ADC)和信号转导抑制剂(IST)。一些MAT与眼表(OS)不良事件(AE)有关,这些不良事件会导致严重的不适,甚至导致视力丧失。虽然这些并发症仍然很罕见,但它们可能被低估了。由于接受MAT治疗的患者数量不断增加,肿瘤学家和眼科医生在实践中都可能遇到与MAT相关的OS AE。快速识别OS AE至关重要,因为早期干预可以控制这些情况,避免视力下降,减少对生活质量(QoL)的负面影响。我们讨论了归因于MATs的OS病理特征,描述了可疑的潜在病理生理机制,并概述了治疗的主线。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ocular surface toxicities associated with modern anticancer therapies

Cancer treatments have recently shifted from broad-spectrum cytotoxic therapies to more focused treatments, maximizing anticancerous activity while reducing toxicity to healthy cells. These modern anticancer therapies (MATs) encompass a wide range of innovative molecules that include immune checkpoint inhibitors and other targeted anticancer therapies, comprising antibody drug conjugates and inhibitors of signal transduction. Some MATs are associated with ocular surface adverse events that can cause severe discomfort and even lead to loss of vision. While these complications remain rare, they are probably underreported. It is likely that both oncologists and ophthalmologists will come across MATs-associated ocular surface-adverse events in their practices, owing to the increasing number of patients being treated with MATs. Rapid identification of ocular surface-adverse events is crucial, as early intervention can manage these conditions to avoid vision loss and reduce negative impacts on quality of life. We discuss characteristics of ocular surface pathologies attributed to MATs, describe the suspected underlying pathophysiological mechanisms, and outline the main lines of treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Survey of ophthalmology
Survey of ophthalmology 医学-眼科学
CiteScore
10.30
自引率
2.00%
发文量
138
审稿时长
14.8 weeks
期刊介绍: Survey of Ophthalmology is a clinically oriented review journal designed to keep ophthalmologists up to date. Comprehensive major review articles, written by experts and stringently refereed, integrate the literature on subjects selected for their clinical importance. Survey also includes feature articles, section reviews, book reviews, and abstracts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信